Questions: Fibrinolysis and Tissue Plasminogen Activator

Question 1

A patient with acute ischemic stroke is treated with intravenous tPA. Why does this treatment dissolve the pathological clot without causing uncontrolled bleeding throughout the body?

• A. tPA is chemically targeted to the brain and cannot enter peripheral circulation
• B. tPA activates plasminogen far more efficiently when plasminogen is bound to fibrin in a clot than when both are free in solution, concentrating lytic activity at the clot
• C. tPA specifically recognizes the unique protein signature of pathological clots versus normal fibrin at wound sites
• D. tPA degrades only old, organized fibrin and is inactive against fresh fibrin sealing normal wounds

Answer: (B)

Fibrin-specific activation is the key mechanism. tPA's catalytic efficiency for plasminogen activation is orders of magnitude higher when plasminogen is fibrin-bound than when both proteins are in free solution. Because plasminogen concentrates at forming clots by binding fibrin, tPA generates plasmin predominantly at the clot surface, not diffusely throughout the circulation. This localized activity is why therapeutic tPA can lyse an occlusive clot without immediately dissolving hemostatic plugs everywhere else — though the therapeutic window is narrow, and overdosing does produce systemic bleeding by overwhelming this selectivity.

Question 2

A patient with obesity and type 2 diabetes has significantly elevated plasma PAI-1 levels. What is the clinical implication for their thrombotic risk?

• A. Reduced thrombotic risk — elevated PAI-1 stabilizes clots and prevents spontaneous dissolution
• B. Reduced bleeding risk only — PAI-1 elevation helps maintain hemostasis after injury
• C. Elevated thrombotic risk — high PAI-1 suppresses tPA activity and impairs fibrinolysis, making pathological clots harder to dissolve
• D. No change in thrombotic risk — PAI-1 only affects how quickly clots dissolve, not whether thrombosis occurs

Answer: (C)

PAI-1 is the primary physiological inhibitor of tPA. When PAI-1 is elevated, tPA's fibrinolytic activity is suppressed, meaning clots that form are less efficiently dissolved. This creates a pro-thrombotic state: the formation-to-dissolution balance shifts toward net clot accumulation. Obesity, insulin resistance, and metabolic syndrome are among the strongest drivers of elevated PAI-1 — a mechanism linking metabolic disease to cardiovascular thrombotic risk beyond traditional lipid and pressure factors. Option A captures the misconception that inhibiting fibrinolysis is protective; in fact, it increases net thrombotic risk.

Question 3

D-dimer elevation in a patient's blood test indicates that active clot formation and fibrinolysis are occurring simultaneously, not that fibrinolysis has already resolved the clotting event.

• T. True
• F. False

Answer: True

D-dimers are fragments produced when plasmin cleaves cross-linked fibrin. Their presence in blood requires both active fibrin formation (clotting) AND active fibrinolysis (dissolution) — you need cross-linked fibrin to be made before plasmin can cleave it into D-dimers. Elevated D-dimers therefore signal ongoing clot turnover, not a past event. Clinically, this makes D-dimer a useful screening marker for deep vein thrombosis and pulmonary embolism, where active thrombosis and simultaneous fibrinolysis produce measurable D-dimer levels. A normal D-dimer makes active thrombosis very unlikely.

Question 4

Elevated PAI-1 levels are protective against thrombosis because PAI-1 inhibits plasmin, preventing it from prematurely dissolving clots that are needed for hemostasis.

• T. True
• F. False

Answer: False

This inverts the mechanism. PAI-1 inhibits *tPA* (the activator of plasminogen), not plasmin directly — though the ultimate effect is less plasmin generation. More importantly, while moderate PAI-1 activity is indeed part of normal hemostatic balance, *elevated* PAI-1 (as seen in metabolic syndrome, obesity, and insulin resistance) tips the balance toward impaired fibrinolysis and pro-thrombotic risk. Pathological clots are less readily dissolved, increasing the risk of thrombotic events. The rare genetic deficiency of PAI-1, by contrast, causes excessive bleeding — confirming that PAI-1 is necessary for normal hemostasis, but that excess PAI-1 is harmful, not protective.

Question 5

A patient presents with acute ischemic stroke 6 hours after symptom onset. Explain the biological reasons a physician might decide not to administer tPA despite its proven efficacy.

Model answer: Two biological rationales support withholding tPA after the therapeutic window (typically 3–4.5 hours). First, clot composition changes over time: fresh fibrin is cross-linked but accessible to fibrinolysis, whereas older organized clots become progressively remodeled and resistant to plasmin. After several hours, the clot may not dissolve effectively even with high tPA doses. Second, prolonged ischemia (>4–6 hours) causes irreversible neuronal death and disrupts the blood-brain barrier. Reperfusing ischemic but not-yet-dead tissue is beneficial; reperfusing dead or severely damaged tissue produces hemorrhagic transformation — blood extravasates through damaged vessel walls, converting an ischemic injury into a hemorrhagic one. Beyond the therapeutic window, the risk of fatal hemorrhage exceeds the potential benefit of reperfusion.

This question requires applying the narrow therapeutic window concept mechanistically. The two reasons — clot age reducing fibrinolytic susceptibility, and ischemia-induced barrier disruption increasing hemorrhage risk — are distinct biological constraints, not just a clinical convention. Understanding them explains why earlier treatment is better and why the cutoff exists.